Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 46.50
Bid: 46.00
Ask: 47.00
Change: -0.25 (-0.53%)
Spread: 1.00 (2.174%)
Open: 45.75
High: 46.50
Low: 45.50
Prev. Close: 46.75
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Omega Wins First Order For Antibody Test

Tue, 09th Jun 2020 11:14

(Alliance News) - The following is a round-up of updates by London-listed companies on the impact of the Covid-19 pandemic, issued on Tuesday and not separately reported by Alliance News:

----------

Avacta Group PLC - Wetherby-based Affimer biotherapeutics developer - Bead-assisted mass spectrometry diagnostics test for Covid-19 infection being developed with partner Adeptrix has reached prototype stage, and can detect the coronavirus spike protein in model sample in the range appropriate for a clinical diagnostic test. Next development step is evaluate and optimise assay before moving to manufacturing and clinical validation.

----------

Omega Diagnostics PLC - Alva-based medical diagnostics - Expects Ebitda for year ended March between GBP850,000 to GBP900,000, ahead of market expectations and up from GBP199,668. Signs long-term supply agreement with Mologic Ltd, for the supply of raw materials for Omega to manufacture its CE-Marked ELISA antibody test. Also signs material transfer agreement with Mologic. Announces first order for test to Senegal worth GBP100,000.

----------

Braveheart Investment Group PLC - Barnsley-based investment holding firm - Paraytec announces that the required affinity macromolecule an aptamer that bonds to the SPIKE glycoprotein on the surface of the Covid-19 virus has been synthesised and supplied to Paraytec from the University of Sheffield. Paraytec expects to complete the production of SPIKE protein in cell factories, and modification of test surface with aptamer in one month.

----------

Ilika PLC - Romsey-based solid-state battery firm - Trading for year ended April 30 in line with expectations. Revenue expected to be GBP2.8 million, up from GBP2.6 million, and narrowed Lbitda of GBP2.1 million from GBP2.2 million. Romsey headquarters remains open throughout lockdown period, while data analytics and business discussions have continued remotely. Expects Stereax pilot line at University of Southampton to reopen shortly.

----------

Sosandar PLC - Cheshire-based women's clothing retail - Reports strong growth in first two months of financial year ending March 31, 2021 despite challenges. Order growth for two months to May 31 up 44% year-on-year, revenue grows by 62%. Increased traffic up 98%, but lower levels of conversion. Marketing expenses reduced, 60% of workforce furloughed, board remuneration reduced. For recently ended year, expects revenue to be at least GBP9 million, up from GBP4.4 million.

----------

SigmaRoc PLC - London-based construction materials - For five months ended May, reports revenue of GBP42 million. In April and May, restriction in Channel Islands lifted allowing Ronez operations to resume more normal trading. In UK, PPG and South Wales platforms scaled up towards full production at end of April and into May. Belgium operations remained active, despite lower activity level.

----------

S&U PLC - Birmingham-based motor finance & property bridging lender - In Advantage Finance, sales for financial year-to-date down to 15% of normal levels due to plummeting car usage, closure of car dealers and ceasing of deliveries, But transactions have now recovered to around 40% of normal. In Aspen Bridging, transaction numbers under a quarter of those budgeted in the year. Improvement seen in both segments.

----------

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
1 Jun 2021 11:16

Avacta confident despite filing delay for Covid-19 antigen test

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group updated the market on its CE-mark submission for its 'AffiDX' SARS-CoV-2 antigen lateral flow test for professional use.

Read more
28 May 2021 11:29

Avacta still waiting on response from UK regulator over Covid test

Avacta still waiting on response from UK regulator over Covid test

Read more
28 May 2021 07:29

Avacta still waiting on MHRA approval for Covid-19 test

(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group responded to speculation around the CE-mark submission for its SARS-CoV-2 antigen lateral flow test on Friday.

Read more
10 May 2021 11:13

IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"

IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"

Read more
22 Apr 2021 12:17

Avacta sees Covid-19 tests driving earnings after reporting 2020 loss

Avacta sees Covid-19 tests driving earnings after reporting 2020 loss

Read more
20 Apr 2021 15:18

Avacta reports positive data for Covid-19 test product

(Sharecast News) - Diagnostics and cancer therapies developer Avacta announced positive data from the clinical validation of its 'AffiDX' SARS-CoV-2 antigen lateral flow test on Tuesday.

Read more
20 Apr 2021 12:17

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

Read more
20 Apr 2021 11:35

AIM WINNERS & LOSERS: Warpaint tops outlook; Avacta's Covid test works

AIM WINNERS & LOSERS: Warpaint tops outlook; Avacta's Covid test works

Read more
15 Apr 2021 14:56

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
6 Apr 2021 13:53

IN BRIEF: Avacta in global Affimer distribution agreement with Abcam

IN BRIEF: Avacta in global Affimer distribution agreement with Abcam

Read more
6 Apr 2021 11:03

Avacta signs global distribution deal with Abcam

(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group has entered into a global distribution agreement with Abcam, it announced on Tuesday, to sell its recently-developed SARS-CoV-2 research 'ELISA Affimer' reagents.

Read more
25 Mar 2021 15:57

EXECUTIVE CHANGES: Ten Entertainment, Emmerson chairs step down

EXECUTIVE CHANGES: Ten Entertainment, Emmerson chairs step down

Read more
9 Mar 2021 20:19

IN BRIEF: Avacta Group signs diagnostic licensing deal with Biokit

IN BRIEF: Avacta Group signs diagnostic licensing deal with Biokit

Read more
9 Mar 2021 11:08

Avacta enters licence deal with Werfen subsidiary Biokit

(Sharecast News) - Cancer therapy and diagnostics developer Avacta has entered into a licence agreement with Werfen subsidiary Biokit, it announced on Tuesday, to incorporate 'Affimer' reagents into a Biokit in-vitro diagnostic product.

Read more
8 Mar 2021 19:07

IN BRIEF: Avacta's Covid antigen test confirmed to detect variants

IN BRIEF: Avacta's Covid antigen test confirmed to detect variants

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.